PACTR202310615330649Other3 期
Open-label, phase 3 study to evaluate the effectiveness of heterologous mRNA-1273 boosting of the single or two dose Ad26.COV2.SCOVID-19 vaccine among health care workers in South Africa
适应症
试验速览
- 阶段
- 3 期
- 状态
- Other
- 发起方
- Moderna Inc
- 入组人数
- 15,000
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 19 Year(s) 至 44 Year(s)（—）
- 性别
- All
入选标准
- •Inclusion criteria
- •Age 18 and older at time of enrolment
- •Sisonke participant
- •Received a priming Ad26.CoV2.S vaccination as part of the Sisonke study
- •If received a second dose of Ad26.CoV2.S vaccine as part of the Sisonke 2 study, this was administered at least 3 months ago
- •Participants who are pregnant or report breastfeeding at the time of enrolment may be included.
- •Willingness and ability to comply with vaccination plan and other study procedures.
- •Capable and willing to provide informed consent
排除标准
- •Exclusion criteria
- •Participants who have received any COVID-19 vaccines other than one or two doses of Ad26.CoV2.S through other means (for example, another mRNA booster dose).
- •Current participation in any other research studies (other than Sisonke) that would interfere with the objectives of this study. The determination of whether participation in another study would be exclusionary for a given participant will be made by the PI/designee.
- •Occurrence of a known COVID-19 outcome within 14 days of enrollment
- •Participants with a history of heparin-induced thrombocytopenia, or thrombosis and thrombocytopenia syndrome (TTS).
- •History of severe adverse reaction associated with a vaccine and/or severe allergic reaction (e.g., anaphylaxis) to any component of mRNA-1273.
- •Pregnancy which began prior to or within 30 days after the receipt of dose 2 of Ad26.COV2 and ongoing at the time of enrolment in this trial.
- •Acute infection (e.g. febrile illness) unless resolved before enrolment.
- •Any significant acute or chronic medical condition, situation or circumstance that in the opinion of the PI/designee makes the participant unsuitable for participation in the study, or jeopardises the safety or rights of the participant
- •The following participants should only be enrolled after discussion with the PSRT:
- •Participants who are thought to have suffered a neurological or cardiac AE considered related to the Ad26.CoV2.S vaccine.
- •Participants reporting a non-infective SAE within the first 28 days following the first or second dose of Ad26.CoV2.S vaccine in the Sisonke 3B trial
- •History of myocarditis or pericarditis especially in young male
- •Chronic history of severe clotting disorders
- •Participants who suffered a thromboembolic AE following the Janssen Covid-19 vaccine.
- •In the event of a clinical contraindication to receiving a heterologous mRNA-1273 booster, the study PSRT, comprising of medical experts in haematology, allergology and neurology supported by sa
研究者
相似试验
进行中（未招募）
3 期
A Study of TAK-625 for the Treatment of Alagille Syndrome (ALGS)Alagille Syndrome (ALGS)JPRN-jRCT2051220098Shikamura Mitsuhiro7
招募中
3 期
A Study of Vedolizumab, given every 4 weeks, in Japanese Participants with Moderate to Severe Ulcerative Colitis or Crohn's Diseaselcerative Colitis, Crohn's DiseaseJPRN-jRCT2031200371Shikamura Mitsuhiro158
进行中（未招募）
3 期
A Study of TAK-625 for the Treatment of Progressive Familial Intrahepatic Cholestasis (PFIC)Progressive Familial Intrahepatic Cholestasis (PFIC)JPRN-jRCT2031220356Shikamura Mitsuhiro5
进行中（未招募）
1 期
Efficacy and Safety Study of Pegylated Interferon Lambda-1a with Ribavirin and Daclatasvir, to treat na?ve subjects with chronic HCV Genotypes 1, 2, 3, and 4 who are co-infected with HIV.Chronic Hepatitis C Virus (HCV) Infection (Genotypes 1, 2, 3, 4)MedDRA version: 16.0Level: PTClassification code 10008912Term: Chronic hepatitis CSystem Organ Class: 10021881 - Infections and infestationsEUCTR2012-003280-22-BEBristol-Myers Squibb International Corporation300
进行中（未招募）
1 期
Efficacy and Safety Study of Pegylated Interferon Lambda-1a with Ribavirin and Daclatasvir, to treat na?ve subjects with chronic HCV Genotypes 1, 2, 3, and 4 who are co-infected with HIV.EUCTR2012-003280-22-GBBristol-Myers Squibb International Corporation453